Aseptic dry-fill manufacturing for ceftiofur sodium injection is configured with a 316L stainless-steel solution vessel jacketed at 5 °C ± 2 °C, a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm PVDF sterilising filter, and a peristaltic filling station installed inside an isolator that maintains ISO 5 particulate conditions under positive pressure. Bulk ceftiofur sodium is dissolved in chilled Water for Injection to a concentration equivalent to 50 mg ceftiofur per mL after reconstitution, filtered into depyrogenated Type I borosilicate vials, and dried under aseptic conditions because the β-lactam ring of ceftiofur sodium is not compatible with terminal steam sterilisation or gamma irradiation without unacceptable degradation. Fill volume is calculated from dried solids content after drying so that each vial delivers 1 g or 4 g ceftiofur equivalents after reconstitution with 20 mL or 80 mL Sterile Water for Injection. Residual moisture is the most critical process parameter because β-lactam hydrolysis in ceftiofur sodium is a pseudo-first-order reaction that accelerates when water activity inside the sealed vial increases; stopper moisture is controlled below the registered stability threshold, and dry powder samples are tested by Karl Fischer titration according to USP <921>. Sub-visible particulate control follows USP <788>, visible particulate inspection follows USP <790>, sterility testing follows USP <71>, and bacterial endotoxin limits are verified by USP <85>. The principal production-line conflict is narrowing filtration flux when solution temperature drifts above 8 °C and soluble degradation precursors raise differential pressure across the sterilising filter; this is managed by increasing filter area per litre of batch, reducing batch size, and holding the solution at 2–8 °C for no longer than the validated holding time. The terminal product is a sterile white to off-white powder in a sealed vial intended for intramuscular or subcutaneous injection in cattle, swine, sheep, and goats after reconstitution to 50 mg ceftiofur equivalents per mL.

What Conditions Trigger Cake Collapse During Primary Drying of Ceftiofur Sodium Injection?

Freeze-dried ceftiofur sodium vials are manufactured when rapid reconstitution and low insoluble particle counts are required in field administration. The filled solution is loaded onto a shelf lyophiliser with shelf temperature capability from −45 °C to +40 °C. Freezing is performed at a controlled ramp of 0.5 °C/min to −40 °C, followed by a hold period sufficient to ensure complete solidification. When mannitol is included as a bulking agent, an annealing step at −10 °C is introduced because mannitol crystallises exothermically and uncontrolled crystallisation can generate vial stress or uneven ice structure. Primary drying is conducted at shelf temperatures between −25 °C and −15 °C with chamber pressure held between 100 mTorr and 200 mTorr; the product temperature must remain below the collapse temperature of the amorphous phase, which for a ceftiofur sodium–mannitol formulation is determined by freeze-drying microscopy rather than assumed from excipient data. If the product temperature exceeds the collapse temperature, the dried cake shrinks and forms a dense glassy plug that increases reconstitution time beyond 60 seconds and releases visible particles. Production-scale lyophilisers introduce measurable thermal asymmetry: edge vials receive additional radiant heat from chamber walls and may dry faster, while centre vials can show slower sublimation due to higher local vapour pressure. This asymmetry forces the primary drying cycle to run at a lower shelf setpoint than laboratory freeze-drying data would suggest; a production cycle may require an additional 4 to 8 hours of primary drying to maintain collapse-free product across the entire shelf. Secondary drying is conducted at +25 °C to +30 °C for 6 to 12 hours, with endpoint confirmation by Karl Fischer moisture below the registered limit, commonly below 1.0% w/w for ceftiofur sodium. Stoppers are closed under vacuum or dry nitrogen to prevent moisture ingress during handling. The terminal product is a sterile lyophilised cake in a Type I glass vial with a bromobutyl closure system, reconstituted to 50 mg ceftiofur equivalents per mL before injection.

Because ceftiofur sodium contains a β-lactam ring that is acid-labile and a carboxylate group that remains ionised at intestinal pH, immediate-release oral tablet formulation without a functional coating is not a viable registered dosage form in most jurisdictions. Roller-compacted granules are prepared from ceftiofur sodium, microcrystalline cellulose, and croscarmellose sodium by dry granulation at roll force of 25–45 kN/cm; aqueous granulation is avoided because free water initiates β-lactam ring opening and generates degradants that are difficult to control during scale-up. The compacted ribbons are milled through a 0.8 mm screen and blended with sodium stearyl fumarate at 1.0% w/w as a lubricant; magnesium stearate is excluded from some prototype blends because its hydrophobic surface can retard drug release from the tablet core. Compression is performed on a rotary tablet press at 60–80 MPa to produce tablets with hardness of 60–80 N and friability below 0.5%. The tablet core is coated with an enteric methacrylic acid copolymer film at a target weight gain of 8% to 12% using a perforated pan coater with inlet air temperature 35–40 °C and bed temperature 28–32 °C. Enteric protection is tested by two-stage dissolution according to USP <711>: after 2 hours in 0.1 N hydrochloric acid, not more than 10% of the labelled ceftiofur content should be released, followed by at least 75% release at 60 minutes in pH 6.8 phosphate buffer. Uniformity of dosage units is monitored by USP <905>. The terminal product is a coated tablet intended for oral administration in companion animals; however, registered commercial oral ceftiofur sodium tablets are not widely available, and published bioavailability data for such tablet formulations are limited.

Capsule Fill Weight Uniformity for Ceftiofur Sodium Dry Granulates at 25 mg Label Claim

Hard gelatin capsule filling of ceftiofur sodium is performed on a dosator capsule machine with powder bed height controlled to maintain consistent fill weight. The needle-shaped or acicular crystal habit of ceftiofur sodium reduces flowability and increases segregation risk during hopper discharge; the API is therefore dry-granulated with lactose monohydrate and pregelatinised starch to produce a free-flowing granulate with a bulk density of 0.55–0.65 g/cm³. The granulate is milled to a D90 below 250 µm and filled into size 3 hard gelatin capsules at 25 mg ceftiofur equivalents per capsule. Fill weight uniformity is verified according to USP <905> mass variation and content uniformity; potential segregation is checked by sampling the beginning, middle, and end of the hopper and assaying ceftiofur sodium content. The capsule filling suite is maintained below 30% RH because hard gelatin shells equilibrate with ambient moisture and can transfer water to the granulate, accelerating ring-opening hydrolysis. The filled capsules are sealed in aluminium-aluminium blisters with a desiccant pouch. The terminal product is a hard gelatin capsule for investigational oral delivery of ceftiofur sodium in dogs or swine; because published pharmacokinetic data for oral capsule formulations of ceftiofur sodium are limited, bioavailability and safety must be established for each target species before any clinical use.

In fluid-bed spray granulation for drinking-water granules, aqueous binder is replaced by ethanolic povidone K-30 solution because water accelerates β-lactam hydrolysis in ceftiofur sodium. Povidone K-30 is dissolved in ethanol at 5% w/w and sprayed onto a fluidised mixture of ceftiofur sodium, mannitol, and sodium citrate in a top-spray fluid-bed dryer at inlet air temperature 40–45 °C and product temperature 28–32 °C. The granulation endpoint is set at a granule D50 of 300–400 µm and residual ethanol below 5000 ppm according to ICH Q3C Class 3 residual solvent limits and USP <467>. The dried granules are passed through a 1.0 mm screen, blended with colloidal silicon dioxide at 0.5% w/w as a glidant, and filled into sachets under nitrogen. Each sachet is designed to be reconstituted with 100 mL of potable water to produce a suspension containing 50 mg ceftiofur equivalents per 5 mL; homogeneity is checked by repeated sampling over 30 minutes to confirm that the dispersed granules do not settle into a non-uniform layer. The terminal product is a granule-filled sachet for oral suspension intended for young ruminants or swine; however, oral ceftiofur sodium granules are not a mainstream registered dosage form, and the low oral bioavailability of ceftiofur sodium in monogastric species must be considered during formulation development.